Medtronic Shareholders Approve Proposals Related to Medtronic's Acquisition of Covidien

From Medtronic:

Medtronic Shareholders Approve Proposals Related to Medtronic's Acquisition of Covidien

MINNEAPOLIS - Jan. 6, 2015 - Medtronic, Inc. (NYSE: MDT) announced that all proposals related to Medtronic's acquisition of Covidien were approved by Medtronic's shareholders today.  Based on preliminary vote results, the proposal to adopt the transaction agreement and approve the merger was approved by shareholders owning approximately 95.66 percent of the shares voted at the meeting and approximately 75.18 percent of the outstanding Medtronic shares as of the record date.  The final vote results will be filed on a Form 8-K with the Securities and Exchange Commission on Friday, January 9, 2015. Covidien announced earlier today that its shareholders had approved the transaction. The transaction is expected to close in the last week of January or early February, subject to approval by the High Court of Ireland. "We are extremely pleased with the positive vote we received today by our shareholders," said Omar Ishrak, chairman and CEO of Medtronic.  "We are convinced that the addition of Covidien's people and technologies will allow us to expedite our strategic initiatives and will allow us to treat more people, in more ways and in more places around the world.  We look forward to closing this transaction by the end of January or early February."  ABOUT MEDTRONIC Medtronic, Inc. (www.medtronic.com), headquartered in Minneapolis, is the global leader in medical technology - alleviating pain, restoring health, and extending life for millions of people around the world.